Article3 Biotech2026
Eco-sustainable chitosan/polyvinyl alcohol nanofibrous mats enriched with
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the therapeutic efficacy of electrospun chitosan/polyvinyl alcohol nanofiber dressings loaded with Corallina officinalis extract (CS/PVA/COE) to enhance diabetic wound healing. Thirty rats were allocated to five groups: normal foot ulcer, diabetic foot ulcers (DFUs), DFUs treated with COE, DFUs treated with CS/PVA nanofibers, and DFUs treated with CS/PVA/COE nanofibers. Wound healing was assessed through macroscopic evaluation of wound closure, biochemical analysis of oxidative stress and inflammatory markers, histopathological and morphometric examination, and immunohistochemical assessment of angiogenic markers (VEGF and CD31). Untreated DFUs exhibited markedly delayed wound closure, persistent inflammation and oxidative stress, impaired collagen deposition, and reduced angiogenesis, as demonstrated by elevated IL-6 and MPO levels, increased MDA and NO levels with depleted GSH, SOD, CAT, and GST defenses, reduced collagen deposition on histological and morphometric examination, and decreased VEGF and CD31 expression, respectively, together with elevated MMP-2, indicating dysregulated extracellular matrix remodeling. In contrast, CS/PVA/COE nanofiber treatment significantly accelerated wound contraction and tissue regeneration, reduced MDA, NO, MPO, and IL-6 levels, and restored GSH, SOD, CAT, and GST antioxidant defenses. Histological and morphometric analyses showed enhanced fibroblast activity, collagen deposition, granulation tissue formation, and re-epithelialization. These improvements were accompanied by increased expression of VEGF and CD31, indicating enhanced angiogenesis. During remodeling, CS/PVA/COE treatment reduced MMP-2 expression and promoted organized collagen deposition and maturation, thereby improving tissue architecture. In conclusion, CS/PVA/COE nanofiber dressings improved the resolution of inflammation, redox balance, angiogenesis, collagen deposition, and extracellular matrix remodeling, supporting their potential as marine-derived nanofibrous dressings for diabetic wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.